Your browser doesn't support javascript.
Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.
Shahrajabian, Mohamad Hesam; Sun, Wenli; Cheng, Qi.
  • Shahrajabian MH; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China.
  • Sun W; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China.
  • Cheng Q; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China.
Hum Vaccin Immunother ; 17(1): 62-83, 2021 01 02.
Article in English | MEDLINE | ID: covidwho-1066194
ABSTRACT
SARS-CoV-2, the virus causing COVID-19, is a single-stranded RNA virus belonging to the order Nidovirales, family Coronaviridae, and subfamily Coronavirinae. SARS-CoV-2 entry to cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which includes Bat SARS-like coronavirus, SARS-CoV and MERS-CoV. A vaccine should induce a balanced immune response to elicit protective immunity. In this review, we compare and contrast these three important CoV diseases and how they inform on vaccine development.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Middle East Respiratory Syndrome Coronavirus / SARS-CoV-2 Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Hum Vaccin Immunother Year: 2021 Document Type: Article Affiliation country: 21645515.2020.1797369

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus / Middle East Respiratory Syndrome Coronavirus / SARS-CoV-2 Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Hum Vaccin Immunother Year: 2021 Document Type: Article Affiliation country: 21645515.2020.1797369